Ondine Announces Share Consolidation and Name Change
11 Oktober 2010 - 8:00AM
UK Regulatory
TIDMOBP
Ondine Announces Share Consolidation and Name Change
FOR: ONDINE BIOPHARMA CORPORATION
TSX, AIM SYMBOL: OBP
October 11, 2010
Ondine Announces Share Consolidation and Name Change
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 11, 2010) - Ondine Biopharma Corporation
(TSX:OBP)(AIM:OBP) (the "Company") today announced that the Company has received Toronto Stock
Exchange acceptance and will proceed with the consolidation of all of its issued and outstanding
common shares on the basis of fifteen (15) "old" common shares for one (1) "new" common share (the
"Consolidation") and the name change from "Ondine Biopharma Corporation" to "Ondine Biomedical Inc.".
Fractional shares remaining after giving effect to the Consolidation will be cancelled, such that
shareholdings of each shareholder will be rounded down to the nearest whole number of post-
consolidation common shares.
The shares of the Company will commence trading on the TSX and on the AIM Market of the London Stock
Exchange on a consolidated basis under the new name "Ondine Biomedical Inc." at the opening of trading
on Thursday, October 14, 2010. The CUSIP number for the Company's post-consolidation common shares is
68234M106. The Company's trading symbol, OBP, will not change.
About Ondine Biopharma Corporation
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial,
fungal and viral infections. The Company is focused on developing leading edge products utilizing its
patented light-activated technology, primarily for the Hospital Acquired Infection (HAI) market.
Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and
spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a
research and development laboratory in Bothell, Washington, USA. For additional information, please
visit the Company's website at: www.ondinebio.com.
-30-
FOR FURTHER INFORMATION PLEASE CONTACT:
Ondine Biopharma Corporation
Carolyn Cross
Chairman and Chief Executive Officer
(604) 669-0555
ccross@ondinebiopharma.com
www.ondinebio.com
OR
Canaccord Genuity Limited
Nominated Adviser
Ryan Gaffney
+4420 7050 6500
The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of
this release.
Ondine Biopharma Corporation
Ondine Biomed (LSE:OBP)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Ondine Biomed (LSE:OBP)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über Ondine Biomed (Londoner Börse): 0 Nachrichtenartikel
Weitere Ondine Bio. News-Artikel